Highmark is First in Pennsylvania to Approve Coverage for New Wound Therapy

Share Article

Pennsylvanians with Highmark Blue Cross/Blue Shield insurance are the first in the State to enjoy coverage for TheraSkin®, a biologically active real skin wound therapy that jumpstarts healing of non-performing wounds. TheraSkin® clinical results are excellent, and demonstrate the potential to save many diabetic patients from life-threatening lower limb amputations. TheraSkin® is a potent new weapon in the battle against rising healthcare costs, with potential to save patients and the US healthcare system more than one billion dollars over the next decade.

Soluble Systems, LLC announced today that Highmark Blue Cross/Blue Shield, a major private insurer in Pennsylvania, provided coverage for the use of TheraSkin in the treatment of poorly healing diabetic foot ulcers, venous leg ulcers, and other difficult to heal wounds, such as pressure sores, skin cancer excision (e.g. Mohs Surgery), large surgical wounds, radiation compromised wounds and necrotizing fasciitis.

This is good news for the estimated 27% of Pennsylvanians who have diagnosed or undiagnosed diabetes. Diabetics are likely to develop diabetic foot ulcers and venous leg ulcers. These ulcers are often extremely difficult to heal and when all else fails, are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.

TheraSkin, a real skin therapy, offers real help. A recently published peer-reviewed research study involving 188 patients shows that TheraSkin healed over 60% of these “non-healing” ulcers in 12 weeks, typically with an average of five or fewer applications.

Importantly, Highmark’s decision to cover TheraSkin provides health care practitioners and patients in Pennsylvania a new weapon in the battle to effectively treat chronic wounds and reduce health care costs. TheraSkin is good for the healthcare pocket book. Because the product is 50 to 70 percent less expensive than substitute products, the US healthcare system could potentially save more than a billion dollars over the next decade by utilizing the healing benefits of TheraSkin.

Soluble Systems, LLC has partnered with the Skin and Wound Allograft Institute (SWAI), a wholly owned subsidiary of LifeNet Health, to bring TheraSkin to market. LifeNet Health is the world’s largest provider of bio-implants and organs for transplantation.

Allan Staley, president of Soluble Systems, comments, “Soluble Systems, LLC and SWAI appreciate the work and scientific review conducted by Highmark Blue Cross/Blue Shield that resulted in a decision to provide reimbursement coverage for TheraSkin. We will work tirelessly with medical institutions and practitioners in the Highmark provider network in order to realize the clinical and economic benefits of TheraSkin for their insured population.”

What is TheraSkin? TheraSkin® is a biologically active cryopreserved human skin allograft for non-responsive chronic wounds. TheraSkin’s fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing. TheraSkin is a clinically and cost effective alternative to bioengineered skin substitutes (BSS) currently used to help heal chronic wounds. Like BSS, TheraSkin provides necessary growth factors and cytokines. Unlike BSS, TheraSkin provides a large quantity of essential human collagens in appropriate ratios to support healing.

More About Soluble Systems, LLC: Soluble Systems, LLC is the manufacturer and/or distributor of a line of advanced wound care products. In addition to TheraSkin®, the company markets TheraGauze®. Patented Skin Moisture Rebalancing Technology (SMRT) enables TheraGauze to regulate moisture differentially across a wound bed and to aid in wound healing without maceration. TheraGauze is manufactured in a certified clean room environment pursuant to FDA regulations in Hampton, Virginia. Corporate offices are located in Newport News, Virginia. For additional information about Soluble Systems, please visit http://www.solublesystems.com.

More About SWAI: SWAI, the Skin and Wound Allograft Institute, is a wholly owned non-profit subsidiary of LifeNet Health. It was formed in 2008 to provide high quality bio-implants for patients with acute burns, traumatic injuries and chronic wounds.    LifeNet Health helps to save lives and restore health for thousands of patients each year. We are the world’s most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies—a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process. For additional information about SWAI, please visit http://www.SWAI.org.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

T. Kerry McCarter

Doug Wilson
LifeNet Health
Email >